Join
Live feed
·
PRReleasevia Quantisnow
GSK plc logo
SCYNEXIS Inc. logo

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

ByQuantisnow·Wall Street's wire, on your screen.
GSK· GSK plcSCYX· SCYNEXIS Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GSK (GSK plc), SCYX (SCYNEXIS Inc.) and more on Quantisnow.

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection | Quantisnow